Val­ne­va, Pfiz­er de­lay their Ly­me dis­ease vac­cine sub­mis­sion to 2026

Val­ne­va said Pfiz­er now aims to sub­mit their part­nered Ly­me dis­ease vac­cine can­di­date to US and Eu­ro­pean reg­u­la­tors in 2026, rather than 2025, pend­ing Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER